1. Tegsedi SmPC, October 2019.2. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):22−31.
3. Brannagan TH et al. European Journal of Neurology 2020, 0:1-8. Published online 28th April 2020.
hATTR, Hereditary transthyretin amyloidosis; TTR, transthyretin.
How can you refer a patient onto the Akcea Connect service?
You will need to complete a patient registration form and a prescription (provided to the Trust by Akcea Connect service providers) and send them to the Trust pharmacy. Upon approval, they will be sent to Akcea Connect service providers to arrange the dispensing and delivery of the medication.
The patients will be given a leaflet to explain that their data will be transferred from the NHS to Akcea Connect service providers. All parties involved will have a data sharing agreement. The leaflet will also show patients where to find the privacy notices of the NHS, and Akcea Connect service providers.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
You are about to leave the Akcea Connect website
Akcea Connect is not responsible for any information, statements, or other content you may encounter on third-party websites.